Bernard Thibault

Bernard Thibault

Auto-generated profile, based on publicly available information

Bernard Thibault

Cardiology Department, Montreal Heart Institute , Montreal, QC

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2013 in Circulation
Verified
Journal Article
Open access
PDF file
BTBernard Thibault
Bernard Thibault
FHFrançois Harel
François Harel
ADAnique Ducharme
Anique Ducharme
MWMichel White
Michel White
KEKenneth A. Ellenbogen
Kenneth A. Ellenbogen
PKPaul Khairy
Paul Khairy
Background—: Although the benefits of cardiac resynchronization therapy are well established in selected patients with heart failure and a prolonged QRS duration, salutary effects in patients with narrow QRS complexes remain to be demonstrated. Methods and Results—: The Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) trial is a randomized, double-blind, 12-center study that was designed to compare the effects of active and inactive cardiac resynchronization therapy in patients with severe left ventricular dysfunction and a QRS duration <120 milliseconds. The trial was interrupted prematurely by the Data Safety and Monitoring Board because of futility and safety concerns after 85 patients were randomized. Changes in exercise duration after 12 months were no different in patients with and without active cardiac resynchronization therapy (−0.7 minutes [95% confidence interval (CI), −2.9 to 1.5] versus 0.8 minutes [95% CI, −1.2 to 2.9]; P =0.31]. Similarly, no significant differences were observed in left ventricular end-systolic volumes (−6.4 mL [95% CI, −18.8 to 5.9] versus 3.1 mL [95% CI, −9.2 to 15.5]; P =0.28) and ejection fraction (3.3% [95% CI, 0.7–6.0] versus 2.1% [95% CI, −0.5 to 4.8]; P =0.52). Moreover, cardiac resynchronization therapy was associated with a significant reduction in the 6-minute walk distance (−11.3 m [95% CI, −31.7 to 9.7] versus 25.3 m [95% CI, 6.1–44.5]; P =0.01), an increase in QRS duration (40.2 milliseconds [95% CI, 34.2–46.2] versus 3.4 milliseconds [95% CI, 0.6–6.2]; P <0.0001), and a nonsignificant trend toward an increase in heart failure–related hospitalizations (15 hospitalizations in 5 patients versus 4 hospitalizations in 4 patients). Conclusions—: In patients with a left ventricular ejection fraction ≤35%, symptoms of heart failure, and a QRS duration <120 milliseconds, cardiac resynchronization therapy did not improve clinical outcomes or left ventricular remodeling and was associated with potential harm. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00900549.

27 February 2013 in EP Europace
Verified
Journal Article
Open access
PDF file
BTBernard Thibault
Bernard Thibault
MDMarc Dubuc
Marc Dubuc
PKPaul Khairy
Paul Khairy
PGPeter G. Guerra
Peter G. Guerra
LMLaurent Macle
Laurent Macle
TFTaraneh G. Farazi
Taraneh G. Farazi
Pacing from multiple sites in the left ventricle (LV) may bring about further resynchronization of the diseased heart compared with biventricular (BiV) pacing. We compared acute haemodynamic response (LV dP/dtmax) of multisite and BiV pacing using a quadripolar LV lead. In 21 patients receiving cardiac resynchronization therapy, a quadripolar LV lead and conventional right atrial and ventricular leads were connected to an external pacing system. A guidewire pressure sensor was placed in the LV for continuous dP/dt measurement. Four multisite pacing configurations were tested three times each and compared with BiV pacing using the distal LV electrode. Nineteen patients had useable haemodynamic data. Median increase in LV dP/dtmax with BiV vs. atrial-only pacing was 8.2% (interquartile range 2.3%, 15.7%). With multisite pacing using distal and proximal LV electrodes, median increase in LV dP/dtmax was 10.2% compared with atrial-only pacing (interquartile range 6.1%, 25.6%). In 16 of 19 patients (84%), two or more of the four multisite pacing configurations increased LV dP/dtmax compared with BiV pacing. Overall, 72% of all tested configurations of multisite pacing produced greater LV dP/dtmax than obtained with BiV pacing. Pacing from most distal and proximal electrodes was the most common optimal configuration, superior to BiV pacing in 74% of patients. In the majority of patients, multisite pacing improved acute systolic function further compared with BiV pacing. Pacing with the most distal and proximal electrodes of the quadripolar LV lead most commonly yielded greatest LV dP/dtmax.

1 December 2011 in Circulation
Verified
Journal Article
Closed access
BTBernard Thibault
Bernard Thibault
ADAnique Ducharme
Anique Ducharme
FHFrançois Harel
François Harel
MWMichel White
Michel White
EOEileen O'MEara
Eileen O'MEara
FIfor the Evaluation of Resynchronization Therapy for Heart Failure (GREATER-EARTH) Investigators
for the Evaluation of Resynchronization Therapy for Heart Failure (GREATER-EARTH) Investigators
Background—: Left ventricular (LV) pacing alone may theoretically avoid deleterious effects of right ventricular pacing. Methods and Results—: In a multicenter, double-blind, crossover trial, we compared the effects of LV and biventricular (BiV) pacing on exercise tolerance and LV remodeling in patients with an LV ejection fraction ≤35%, QRS ≥120 milliseconds, and symptoms of heart failure. A total of 211 patients were recruited from 11 centers. After a run-in period of 2 to 8 weeks, 121 qualifying patients were randomized to LV followed by BiV pacing or vice versa for consecutive 6-month periods. The greatest improvement in New York Heart Association class and 6-minute walk test occurred during the run-in phase before randomization. Exercise duration at 75% of peak V o 2 (primary outcome) increased from 9.3±6.4 to 14.0±11.9 and 14.3±12.5 minutes with LV and BiV pacing, respectively, with no difference between groups ( P =0.4327). LV ejection fraction improved from 24.4±6.3% to 31.9±10.8% and 30.9±9.8% with LV and BiV pacing, respectively, with no difference between groups ( P =0.4530). Reductions in LV end-systolic volume were likewise similar ( P =0.6788). The proportion of clinical responders (≥20% increase in exercise duration) to LV and BiV pacing was 48.0% and 55.1% ( P =0.1615). Positive remodeling responses (≥15% reduction in LV end-systolic volume) were observed in 46.7% and 55.4% ( P =0.0881). Overall, 30.6% of LV nonresponders improved with BiV and 17.1% of BiV nonresponders improved with LV pacing. Conclusion—: LV pacing is not superior to BiV pacing. However, nonresponders to BiV pacing may respond favorably to LV pacing, suggesting a potential role as tiered therapy. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00901212.

1 February 2015 in Heart Rhythm
Verified
Journal Article
Closed access
LRLena Rivard
Lena Rivard
GSGernot Schram
Gernot Schram
AAAnita Asgar
Anita Asgar
PKPaul Khairy
Paul Khairy
JAJason G Andrade
Jason G Andrade
BTBernard Thibault
Bernard Thibault

1 July 2019 in Heart Rhythm
Verified
Journal Article
Closed access
BTBernard Thibault
Bernard Thibault
PRPhilippe Ritter
Philippe Ritter
KBKerstin Bode
Kerstin Bode
LCLeonardo Calò
Leonardo Calò
BMBlandine Mondésert
Blandine Mondésert
NVNiraj Varma
Niraj Varma

1 July 2005 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
BTBernard Thibault
Bernard Thibault
DRDenis Roy
Denis Roy
PGPeter G. Guerra
Peter G. Guerra
LMLaurent Macle
Laurent Macle
MDMarc Dubuc
Marc Dubuc
MTMario Talajic
Mario Talajic